Redeye comments on the announcement that Moberg Pharma has signed an exclusive license agreement with Karo Healthcare for the commercialisation of MOB-015/Terclara in 19 European markets. The partnership enables a coordinated pan-European launch under the globally recognised Lamisil brand, substantially expanding Moberg’s market reach. We find both the partner choice and agreement structure very encouraging, as it should fast-track a broad and efficient European rollout.
LÄS MER
